Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used...
Transcript of Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used...
![Page 1: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/1.jpg)
Introduction to experimental
pharmacology:
from in vitro to in vivo studies
![Page 2: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/2.jpg)
Research and development in pharmacology
• Cinical trials
• Preclinical studies
![Page 3: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/3.jpg)
Drug R&D : evolve through steps which take in
consideration all the informations available at that
stage of the study
![Page 4: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/4.jpg)
Conceptual research (natural substances, traditional medicine, drug design,…) Casuale discovery of a new substance (serendipity)
How is a drug born?
![Page 5: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/5.jpg)
Talidomide (N-ftalimido-glutaride) history
• 1950 borns as sedative and hypnotic
• Prescritpion in the control of nausea in pregnancy in the 60s
• 1961 first report of focomelic newborns (10000) (Lancet)
• Drug withdrown
• 1965 use in leprosy male patients for hypnotic use, effective within 4-48 h
• 1989 starts the use as immunomodulator in transplants
• 2000 use in HIV & cancer
Immunomodulator with antiangiogenic proprerties
![Page 6: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/6.jpg)
Other examples…
• Minoxidil (vasodilator via K-channel) designed as antihypertensive drug
used ad drug against alopecia
• Sildenafil (phosphodiesterase inhibitor)
designed as anti-angina drug used for erectile dysfunction/impotence
![Page 7: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/7.jpg)
Conceptual research and discovery of new susbtances
• 1 – 2 years
• Approx 8000 substances potentially active
Research aim
Define and synthetize new susbtance
![Page 8: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/8.jpg)
![Page 9: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/9.jpg)
How?
• Hypotehsis and ideas • Synthesis on lab scale of the susbtances • Screening on cells/tissue of its future
indication • Evaluation and validation in aniaml models
![Page 10: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/10.jpg)
PRECLINICAL STUDIES
• Durantion: 2-3 y
Chemical structure correlation with specific pharmacological action (SAR studies)
resulting in further reduction of the number of molecules under investigation
Select from thousands screened substances
20 – 30 molecules pharmacologically and biochemically interesting
![Page 11: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/11.jpg)
Preclincal pharmacological
research development of potential new drugs
• Pharmacological tests to screen, understand the mechanisms of action, receptor activity and biological efficacy of the new molecules
• Toxicity and pharmacokinetic studies
• Choice of the drugs entering into the clinical trials
TIME: 5-6 y
![Page 12: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/12.jpg)
Pharmacological studies
• Different in relation to the potential
mechanism of action and the class of drugs
in development
• Screening/comprehension of the
mechanisms
• In vitro, ex vivo & in vivo (experimental
animals)
![Page 13: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/13.jpg)
EXPERIMENTAL MODELS to DEFINE the PHARMACOLOGICAL PROFILE of a COMPOUND
1. MOLECULAR LEVEL A. Receptor binding B. Enzymatic activities
2. CELLULAR LEVEL A. Cell cultures B. Isolated tissues (vessels, heart, intestine etc..)
3. ANIMAL MODELS A. Normal animals (mouse, Rat, dog, cat, rabbit, monkey) B. Animal models reproducing the disease
![Page 14: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/14.jpg)
Cellular models and the preclincial development of drugs
1. Primary cell cultures form human and animal source (neurons, hepatocytes, etc)
2. Cells transfected with the proteins target of the drug action (HEK 293, CHO transfected with receptors, ion channels, ttransportes, enzymes)
3. Tumor cells
![Page 15: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/15.jpg)
ANIMAL MODELS REPRODICING the DISEASE CHARACTERISTICS and DRUG EVALUATION
1. Transgenic mice: Animals in which an exogenous gene (transgene) normal or mutated, is added to the genome and expressed in a specific tissue
2. “Knockout” mice: Animals in which specific genes are mutated or made inactive (Parkinson, Alzheimer, homozigous for ob gene)
3. Animal Genetically expressing a pathology (hypertensive rats , obese mice, ...)
4. Animals treated with strategy/molecule which reproduce the disease state (rats with flogistic sites, rats with ulcers, diabetic rats, ...
![Page 16: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/16.jpg)
IN VITRO (examples)
• Enzymatic activities (enzymes isolated from tissues
or cells) to study inhibitors/activators
• Electrophysiology techniques (blockers/activators of
ionic channels)
• Receptor Binding
• Enzymes/second messengers involves in signal
transduction
• Specific cellular functions on normal or transfrmed or
genetically modified cells
![Page 17: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/17.jpg)
EX VIVO (examples)
• Tissues , assessement of integrated
responses
• Tissue slices (es. brain)
• Isolated Organs (preparations from the
heart, vessels, intestinal muscles, excretory
system, reproductive organs )
![Page 18: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/18.jpg)
Animal models (IN VIVO)
mouse Rat rabbit dog Primate
![Page 19: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/19.jpg)
Essential documents for preclinical study
• Protocol (according GLP)
• Study results
• Ethycal clearance (local and national commetee)
![Page 20: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/20.jpg)
PRE-CLINICAL STUDIES
PHASE I
PHASE II
![Page 21: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/21.jpg)
PHASE I
Detailed Pharmacology studies to assess
The main therapeutic effects
Side effects
Acute toxicity
Solubility of susbtance
![Page 22: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/22.jpg)
PHASE II
AIMS
1. pharmacokinetic/dynamic profile
2. Subacute and chronic toxitity 3. Toxicology of reproduction 4. Mutagenesis & cancerogenesis 5. Stability
![Page 23: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/23.jpg)
Toxicological studies to assess the safety of a new drug
ACUTE TOXICITY (single administration at
high doses)
TOXICITY UPON REPEATED ADMINITRATIONS
(1 - 24 mo)
MUTAGENESIS IN VITRO
CLINICAL TRIALS (PHASES I and IIa)
MUTAGENESIS IN VIVO
Special TOXICITIES (for drugs with particular risks)
REPRODUCTIVE TOXICITY (Fertility, theratogenesis)
CANCEROGENESIS (2 Y in mice and rats)
Candidate molecule
![Page 24: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/24.jpg)
Required elements for a toxicological diagnosis
• Clinical signs, body weight, food and water consumption
• Haematolgial exams, clinical analysis
• Ophtamologic and veterinary examinations
• Cardiovascolar (ECG), neurologic (spontanoeus motility, behaviour)
• Organ modification : macroscopic and microscopic inspection (autopsia)
![Page 25: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/25.jpg)
Preclinical results are used for:
• Synthesis of active susbtances at “pilot scale”
• Possibility of scale up synthesis
• Defintion of the final galenic form
• Evaluation of stability of the final pharmaceutical formulation
• Scale-up synthesis for clinical trials
![Page 26: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/26.jpg)
HYPOTHESIS IDEA
Chemical-pharmaceutical data
Laboratory animals
Pharmacodynamic data
Toxicology data
Pharmacokinetic data
Ethycal and clinical evaluation
1. Uomo
![Page 27: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/27.jpg)
Ethycal and strategic criteria to start clinical trials
• Evaluation benefits/risks
• Possibility to transfer the pharmadynamic data obtained on the animal to humans
• Low risk for human in relation to
Potential benefit Urgency to have the new drug
![Page 28: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/28.jpg)
Preclinical Clinical
8000
molecules
1 drug
Pharma cost
(time=10-12 y)
![Page 29: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/29.jpg)
Clinical studies on humans
![Page 30: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/30.jpg)
players Pharmaceutical company
Hospital
University
![Page 31: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/31.jpg)
Pharmaceutical company
Project manager
Quality Assurance
Clinical Research Associate
Forensic dept
Biostatistic dept
Finantial dept
Pharmacovigilance dept
Data Management
Production
![Page 32: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/32.jpg)
Hospital
Ethyical cometee
Pharmacy
Sanitary direction
Medical doctors
University
![Page 33: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/33.jpg)
![Page 34: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/34.jpg)
Clinical trials
• Phase I: healthy individuals/diseased individuals
• Phase II: drug doses and administration routes
• Phase III: drug efficacy
• Phase IV: post marketing
![Page 35: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/35.jpg)
Document requirements to start a clinical trial
• Protocol
• Investigator brochure (IB)
• Clinical data record Form (CRF)
• Information for the subject
• Informed consent form
• Contract
• Insurance
• Autorization (CE)
![Page 36: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/36.jpg)
Phase I
• Generally on healthy subjects
• Limited numeber of participants (20 - 50)
• Short duration
• Allows to define three maxiamally tollerated doses, time of administration in relation to the pharmacokinet data, galenic form
![Page 37: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/37.jpg)
Phase II
• Patients affected by the pathology
• Limited number of patients for a short period
• Allows to define the best dose regimen
• The pharmacological activity can be compared to the placebo or a reference drug
![Page 38: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/38.jpg)
Phase III
• Patients with the target pathology
• Large numbers of patients
• It allows to define the efficacy of the drug
• time……..
![Page 39: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/39.jpg)
Phase III
• time….. depends on the pathology and the reference treatment
• Drug for Depression: 4w – 6 m
• Drug for Hypertension: >3 – 6 m
• Drug for Diabetes: 6 m – 1 y
• Drug for Osteoporosis: 4 – 5 y
![Page 40: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/40.jpg)
Phase III
CONTROL group usually required based on the aim of the study:
• Absolute efficacy
• Comparative evaluation
• Risk/benefit
• Safety
![Page 41: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/41.jpg)
Phase III
4 types of control:
• Versus placebo
• Versus no treatment
• Dose-response
• Active Control
![Page 42: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/42.jpg)
Phase III Placebo / no treatment: Advantages: it allows to demontrate the absolute
efficacy and safety; shows the maximum of efficacy, reduction of the numenr of involved subjects, minimum of the systemic error coming form the expectancies of the patient and researcher.
Disadvantages: ethycal problems, lack of comparison with
existing therapies.
![Page 43: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/43.jpg)
Phase III
Dose - response:
Patients are assigned casually to a certain dose, with or w/o placebo. The efficacy is based on the statistical comparisons between doses and with placebo.
![Page 44: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/44.jpg)
Phase III
Active control: • Drug already in the market • obligatory • Necessary at least to demonstrate the not-
inferiority • best tolerability • To establish the price of the new drug
![Page 45: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/45.jpg)
Phase IV
• post marketing study=pharmacovigilance
• Allow to evaluate the development of toxic effects at low frequency not detected during the phase II and III clinical trials.
![Page 46: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/46.jpg)
Problems linked to the development of a new drug
• Lack of efficacy
• Toxic effects in : Cellular models, animals, human
• Manufacturing problems:
impurities
Degradation products,
Unexpected metabolites during synthetic process
![Page 47: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/47.jpg)
………more
• Problems related to the pharmaceutic form: stability, Difficulties of formulation
• Mild or limited efficiay in a very competitive market
• Changes in the therapeutic approach to the pathology
![Page 48: Introduction to experimental pharmacology: from in vitro ... · designed as anti-angina drug used for erectile dysfunction/impotence . Conceptual research and ... development of potential](https://reader030.fdocuments.us/reader030/viewer/2022040300/5e62a3a01a806d04dc093ac9/html5/thumbnails/48.jpg)
FUTURE?
Biotech drugs
Gene Therapy
Cell Therapy
Pharmacogenetics